Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Rezolute, Inc.

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute to Participate in the Jefferies Global Healthcare Conference
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Reports First Quarter Fiscal 2024 Results
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.